12
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 1: Diagnosis

      Read this article at

      ScienceOpenPublisher
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Herpes zoster (HZ, shingles) is a frequent medical condition which may severely impact the quality of life of affected patients. Different therapeutic approaches to treat acute HZ are available. The aim of this European project was the elaboration of a consensus-based guideline on the management of patients who present with HZ, considering different patient populations and different localizations. This interdisciplinary guideline aims at an improvement of the outcomes of the acute HZ management concerning disease duration, acute pain and quality of life of the affected patients and at a reduction of the incidence of postherpetic neuralgia and other complications. The guideline development followed a structured and predefined process, considering the quality criteria for guidelines development as suggested by the AGREE II instrument. The steering group was responsible for the planning and the organization of the guideline development process (Division of Evidence based Medicine, dEBM). The expert panel was nominated by virtue of clinical expertise and/or scientific experience and included experts from the fields of dermatology, virology/infectiology, ophthalmology, otolaryngology, neurology and anaesthesiology. Recommendations for clinical practice were formally consented during the consensus conference, explicitly considering different relevant aspects. The guideline was approved by the commissioning societies after an extensive internal and external review process. In this first part of the guideline, diagnostic means have been evaluated. The expert panel formally consented recommendations for the management of patients with (suspected) HZ, referring to the assessment of HZ patients, considering various specific clinical situations. Users of the guideline must carefully check whether the recommendations are appropriate for the context of intended application. In the setting of an international guideline, it is generally important to consider different national approaches and legal circumstances with regard to the regulatory approval, availability and reimbursement of diagnostic and therapeutic interventions.

          Related collections

          Most cited references74

          • Record: found
          • Abstract: found
          • Article: not found

          The global epidemiology of herpes zoster.

          Varicella-zoster virus (VZV) is a ubiquitous, highly neurotropic, exclusively human α-herpesvirus. Primary infection usually results in varicella (chickenpox), after which VZV becomes latent in neurons of cranial nerve ganglia, dorsal root ganglia, and autonomic ganglia along the entire neuraxis. As humans undergo a natural decline in cell-mediated immunity (CMI) to VZV with age, VZV frequently reactivates to produce zoster, characterized by maculopapular or vesicular rash and dermatomal-distribution pain. Pain and rash usually occur within days of each other. Pain is severe and often burning. Colorful descriptions of zoster exist worldwide. In Arabic, Hezam innar ( ) means belt of fire; in Hindi, Baoisayaa daga ( ) means big rash; in Norwegian, Helvetesild means Hell's fire (also described as a bell of roses from Hell); and in Spanish, Culebrilla means small snake.(1) The most common complication of zoster is postherpetic neuralgia (PHN), operationally defined as pain lasting for more than 90 days after rash. Zoster may be followed by multiple neurologic disorders (meningoencephalitis, myelitis, and vasculopathy, including VZV temporal arteritis) as well as ocular disease (acute or progressive outer retinal necrosis).
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective.

            Herpes zoster (HZ) is primarily a disease of nerve tissue but the acute and longer-term manifestations require multidisciplinary knowledge and involvement in their management. Complications may be dermatological (e.g. secondary bacterial infection), neurological (e.g. long-term pain, segmental paresis, stroke), ophthalmological (e.g. keratitis, iridocyclitis, secondary glaucoma) or visceral (e.g. pneumonia, hepatitis). The age-related increased incidence of HZ and its complications is thought to be a result of the decline in cell-mediated immunity (immunosenescence), higher incidence of comorbidities with age and social-environmental changes. Individuals who are immunocompromised as a result of disease or therapy are also at increased risk, independent of age. HZ and its complications (particularly postherpetic neuralgia) create a significant burden for the patient, carers, healthcare systems and employers. Prevention and treatment of HZ complications remain a therapeutic challenge despite recent advances. This is an overview of the multidisciplinary implications and management of HZ in which the potential contribution of vaccination to reducing the incidence HZ and its complications are also discussed.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The incidence of herpes zoster in a United States administrative database.

              Few recent studies have reported data on the incidence of herpes zoster (HZ) in U.S. general clinical practice. To estimate the age- and sex-specific incidence of HZ among U.S. health plan enrollees. Data for the years 2000 to 2001 were obtained from the Medstat MarketScan database, containing health insurance enrollment and claims data from over 4 million U.S. individuals. Incident HZ cases were identified through HZ diagnosis codes on health care claims. The burden of HZ among high-risk individuals with recent care for cancer, HIV, or transplantation was examined in sub-analyses. Overall incidence rates were age- and sex-adjusted to the 2000 U.S. population. MarketScan U.S. health plan enrollees of all ages. We identified 9,152 incident cases of HZ (3.2 per 1,000 person-years) (95% confidence interval [CI], 3.1 to 3.2 per 1,000). Annual HZ rates per 1,000 person-years were higher among females (3.8) than males (2.6) (P<.0001). HZ rates rose sharply with age, and were highest among individuals over age 80 (10.9 per 1,000 person-years) (95% CI, 10.2 to 11.6). The incidence of HZ per 1,000 person-years among patients with evidence of recent care for transplantation, HIV infection, or cancer (10.3) was greater than for individuals without recent care for these conditions (3.0) (P<.0001). The overall incidence of HZ reported in the present study was found to be similar to rates observed in U.S. analyses conducted 10 to 20 years earlier, after age- and sex-standardizing estimates from all studies to the 2000 U.S. population. The higher rate of HZ in females compared with males contrasts with prior U.S. studies.
                Bookmark

                Author and article information

                Journal
                Journal of the European Academy of Dermatology and Venereology
                J Eur Acad Dermatol Venereol
                Wiley
                09269959
                January 2017
                January 2017
                November 02 2016
                : 31
                : 1
                : 9-19
                Affiliations
                [1 ]Division of Evidence Based Medicine in Dermatology (dEBM); Department of Dermatology, Venereology and Allergy; Charité - Universitätsmedizin Berlin; Berlin Germany
                [2 ]Department of Dermatology; University Medical Center of Liège; Liège Belgium
                [3 ]Department of Dermatology and Venereology; University Hospital Center Zagreb; University of Zagreb School of Medicine; Zagreb Croatia
                [4 ]Department of Anesthesiology; Charité - Universitätsmedizin Berlin; Berlin Germany
                [5 ]Department of Dermatology; Poznan University of Medical Sciences; Poznan Poland
                [6 ]Department of Otorhinolaryngology; The Medical School; University of Malta; Msida Malta
                [7 ]Department of Dermatology and Allergology; University of Szeged; Szeged Hungary
                [8 ]Division of Infection and Immunity; University College London; London UK
                [9 ]Section of Dermatology and Venereology; Department of Medicine; University of Verona; Verona Italy
                [10 ]Department of Dermatology and Venerology; Universitätsklinik Rostock; Rostock Germany
                [11 ]Faculty of Epidemiology and Population Health; London School of Hygiene and Tropical Medicine; London UK
                [12 ]Department of Ophthalmology; Academic Medical Center; University of Amsterdam; Amsterdam The Netherlands
                [13 ]Department of Otolaryngology; University Hospital Aintree NHS Foundation Trust; Liverpool UK
                [14 ]Department of Ophthalmology; Charité - Universitätsmedizin Berlin; Berlin Germany
                [15 ]Department of Neurology; Christian Doppler Medical Center; Paracelsus Medical University; Salzburg Austria
                [16 ]Department of Viroscience; Erasmus MC; Rotterdam The Netherlands
                [17 ]Department of Virology and Antiviral Therapy; Jena University Hospital; Jena Germany
                Article
                10.1111/jdv.13995
                a176be71-bfc5-4438-9f06-62ddd6b0d43e
                © 2016

                http://doi.wiley.com/10.1002/tdm_license_1.1

                http://onlinelibrary.wiley.com/termsAndConditions#vor

                History

                Comments

                Comment on this article